Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus

R DeBusk1, Y Drory, I Goldstein

  • 1Stanford University School of Medicine, Palo Alto, California, USA.

Insights

Patients with cardiovascular disease and sexual dysfunction can resume sexual activity safely if they are low-risk. Intermediate-risk patients need further evaluation, while high-risk patients require cardiac stabilization first.

Area of Science:

  • Cardiology
  • Sexual Medicine

Background:

  • Sexual dysfunction is common and impacts quality of life.
  • A strong link exists between sexual dysfunction and cardiovascular disease (CVD).
  • Sexual activity carries potential cardiac risks.

Purpose of the Study:

  • To develop clinical management recommendations for sexual dysfunction in CVD patients.
  • To stratify CVD patients by cardiac risk for sexual activity and treatment.
  • To provide a physician-guided algorithm for managing sexual dysfunction in CVD.

Main Methods:

  • A consensus panel reviewed research and expert presentations.
  • A cardiac risk stratification system (low, intermediate, high) was developed.
  • An algorithm was created to guide clinical decision-making.

Main Results:

  • Most patients fall into the low-risk category (e.g., controlled hypertension, stable angina, uncomplicated MI).
  • Low-risk patients can resume sexual activity or receive treatment, with caution regarding sildenafil and nitrates.
  • Intermediate-risk patients require further cardiac evaluation; high-risk patients need stabilization before resuming sexual activity or treatment.

Conclusions:

  • A risk-stratification approach enables safe management of sexual dysfunction in CVD patients.
  • Physicians can use the provided algorithm to guide patient care.
  • Addressing sexual dysfunction is crucial for improving well-being in CVD patients.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...